Siltuximab

Definition

A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.

NCIT:C61084 · NCI Thesaurus OBO Edition · CC BY 4.0

Also known as Anti-IL-6 Chimeric Monoclonal Antibody, cCLB8, CNTO 328, CNTO-328, CNTO328, SILTUXIMAB, Sylvant — per NCIT

Also identified as

ATC L04AC11 per RXNORM
NCIT NCIT:C61084 per NCIT
SCTID 704262001 per RXNORM
SCTID 704263006 per RXNORM
UNII T4H8FMA7IM per RXNORM

Indications

Disease	Relation	Source
Castleman disease	may treat	MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ	Side effect / interaction	Source
Lymphoid system	may treat a disease of this organ	DERIVED · CC BY 4.0

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.